Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Vebreltinib for NSCLC (Advanced Non-small Cell Lung Cancer)

To explore the how well it works and safety of vebreltinib plus platinum-doublet chemotherapy as first-line therapy in patients with driver mutation-negative, MET-overexpressing, PD-L1 TPS \< 50%, locally advanced or metastatic NSCLC .

Official registry: https://clinicaltrials.gov/study/NCT07549061 · Shanghai Chest Hospital · enrollment listed as 19

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Vebreltinib, or Chemotherapy. The registry lists allocation as na. To explore the how well it works and safety of vebreltinib plus platinum-doublet chemotherapy as first-line therapy in patients with driver mutation-negative, MET-overexpressing, PD-L1 TPS \< 50%, locally advanced or metastatic NSCLC .

They plan to enroll about 19 people at Shanghai. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Vebreltinib in Combination With Platinum-based Doublet Chemotherapy as First-line Treatment for Driver Mutation-negative, MET-overexpressing, PD-L1 TPS < 50%, Locally Advanced or Metastatic Non-small Cell Lung Cancer: a Prospective, Single-arm, Phase II Study

Interventions: Vebreltinib, Chemotherapy

Primary outcome (registry wording): Objective Response Rate (ORR)

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Patients must meet all of the following who can join:
  • Have histologically or cytologically confirmed NSCLC. (pathology reports from outside institutions are acceptable)
  • Have newly diagnosed locally advanced or metastatic NSCLC that is not amenable to curative surgery or radiotherapy according to the AJCC 9th edition staging system
  • Have no prior systemic anticancer therapy for advanced or metastatic disease. Prior neoadjuvant or adjuvant systemic therapy, definitive chemoradiotherapy or radiotherapy is permitted provided that treatment was completed ≥12 months before recurrence
  • Have an how well you can do daily activities (ECOG score) of 0-2
  • Have MET protein overexpression, defined as moderate-to-strong (2+ or 3+) MET staining in ≥50% of viable tumour cells by IHC
  • Have a PD-L1 TPS \<50%

Public study contact (from the registry)

Wei Nie

021-63846590

niewei-1001@163.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Evaluation for NCI Surgery Branch Clinical Research Protocols

Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.

NCT00001823 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

FAQ about this NCT record

Is NCT07549061 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07549061?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07549061?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary